Skip to main content

Johnson & Johnson free cash flow

  • JNJ · NYSE
  • Healthcare
  • Pharmaceuticals
  • S&P 500
$285.75+0.79%Close 13 Nov 2026 · Market value $684.4B

Johnson & Johnson's free cash flow was $19.7 billion for fiscal year 2025 (the twelve months to 28 Dec 2025), down 0.7% from fiscal 2024.

In the third quarter of fiscal 2026 (the three months to 27 Sep 2026) it was $6.36 billion, down 20.6% from a year earlier.

Over the four quarters to 27 Sep 2026, free cash flow was $20.6 billion.

From Johnson & Johnson's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 21 Oct 2026.

Fiscal 2025
$19.7B
−0.7%
Q3 FY2026
$6.36B
−20.6% on a year
Growth over 9 years
+2.7%
a year, FY 2016–FY 2025

Free cash flow by fiscal year

$15.5BFY 2016$17.8BFY 2017+14.4%$18.5BFY 2018+4.2%$19.9BFY 2019+7.5%$20.2BFY 2020+1.4%$19.8BFY 2021−2.1%$17.2BFY 2022−13.0%$18.2BFY 2023+6.2%$19.8BFY 2024+8.7%$19.7BFY 2025−0.7%

Change on the year before, under each year. From FY 2016 to FY 2025, Johnson & Johnson's free cash flow went from $15.5 billion to $19.7 billion, a compound annual change of +2.7%; the highest was $20.2 billion in FY 2020.

Johnson & Johnson free cash flow, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Free cash flow$15.5B$17.8B$18.5B$19.9B$20.2B$19.8B$17.2B$18.2B$19.8B$19.7B
Period end1 Jan 201731 Dec 201730 Dec 201829 Dec 20193 Jan 20212 Jan 20221 Jan 202331 Dec 202329 Dec 202428 Dec 2025

Free cash flow by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

Johnson & Johnson free cash flow, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Free cash flow$5.37B$3.38B$2.83B$8.01B$5.47B$1.47B$7.29B$6.36B
Period end29 Dec 202430 Mar 202529 Jun 202528 Sep 202528 Dec 202529 Mar 202628 Jun 202627 Sep 2026

How free cash flow is measured

Free cash flow is the cash generated by operations less capital expenditure: the cash a company has left to repay debt, pay dividends, buy back shares or invest. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

Johnson & Johnson's other figures

Free cash flow of comparable companies

Everything on JNJ, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.